Company Overview: Cellectar

Industry News

7 Feb

Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO CEO & Investor Conference in on Monday, February 13th at 2:00 PM ET in the Windsor...

Read more

5 Jan

Cellectar Biosciences to Present at the 9th Annual Biotech Showcase

MADISON, Wis., Jan. 05, 2017 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB), an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 10:00 AM PT in Room 2 (Ballroom Level). “We...

Read more

20 Dec

Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs

MADISON, Wis., Dec. 20, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announces two patent allowances for imaging agents delivered via the company’s patented PDC platform.  The United States Patent and Trademark Office (“USPTO”) issued patent allowances covering method of...

Read more

14 Dec

Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types

MADISON, Wis., Dec. 14, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (“USPTO”) has issued patent allowances covering method of use for radiotherapy with the company’s lead compound, CLR 131, as...

Read more

12 Dec

Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035

MADISON, Wis., Dec. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted patent number 9,480,754 covering the method of use for CLR 1603 to treat breast, lung, colorectal...

Read more

1 Dec

Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies

MADISON, Wis., Dec. 01, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today provides a data update on the first two cohorts of the company’s Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The...

Read more

28 Nov

Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production

MADISON, Wis., Nov. 28, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announced it has selected Hamilton, Ontario-based Centre for Probe Development and Commercialization (CPDC), a well-respected GMP manufacturing organization specializing in radiopharmaceuticals, as a supplier of the company’s lead...

Read more

23 Nov

Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering

MADISON, Wis., Nov. 23, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (“Cellectar” or the “company”), an oncology-focused, clinical stage biotechnology company, today announces the pricing of an underwritten public offering of shares of its common stock, or in lieu thereof, shares of its preferred stock convertible into 66,667...

Read more

17 Nov

Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors

MADISON, Wis., Nov. 17, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that following the successful conjugation of multiple, natural product cytotoxic molecules developed by Pierre Fabre to Cellectar’s PDC delivery platform, it has initiated in vivo studies for...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address